NCT04623398View on ClinicalTrials.gov

Effect of Lithium in Patients With Autism Spectrum Disorder and Phelan-McDermid Syndrome (SHANK3 Haploinsufficiency)

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 21, 2022

Primary Completion Date

August 26, 2024

Study Completion Date

August 26, 2024

Conditions

Autism Spectrum Disorder

Interventions

DRUG

Lithium Carbonate

The experimental drugs in this study will be lithium carbonate capsules dosed at 62.5mg, 125mg and 250mg prepared as hospital preparations for clinical trials.

DRUG

Placebo

Trial Locations (1)

75019

Hôpital Robert Debré, Paris

All Listed Sponsors

lead

Assistance Publique - Hôpitaux de Paris

OTHER